Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer's disease

Drug Discov Today. 2021 Jul 28:S1359-6446(21)00325-1. doi: 10.1016/j.drudis.2021.07.020. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is an irreversible dementia state with characteristic clinical manifestations, including declining cognitive skills and loss of memory, which particularly affects the older population. Despite significant efforts in the field of nano-based drug delivery, there have been few successes achieved in the design of a rational drug therapy. Nanoemulsions (NEs) have potential for the delivery of AD therapeutics owing to their capability for brain drug delivery. Still, there is a long way to go before such therapeutics become a reality in the clinic. In this review, we highlight the preclinical assessment of NEs for AD and discuss the regulatory constraints to their clinical acceptance.PMID:34332094 | DOI:10.1016/j.drudis.2021.07.020

Source: Drug Discovery Today - July 31, 2021 Category: Drugs & Pharmacology Authors: Mayank Handa Sanjay Tiwari Awesh K Yadav Waleed H Almalki Saad Alghamdi Khalid S Alharbi Rahul Shukla Sarwar Beg Source Type: research